Advertisement

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Advertisement


Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Focus on Optimized Dosing of Ibrutinib Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement



Feb
28
Today In Oncology
Familiarity With Complementary and Integrative Therapies Among Patients With Cancer and Caregivers
Two ADAURA Analyses Support the Use of Osimertinib in Patients With Surgically Resected NSCLC
Taiwanese TALENT Study Supports Effectiveness of Low-Dose CT for Lung Cancer in Certain Populations
New Burkitt Lymphoma International Prognostic Index
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside